G. S. Falchook

959 total citations
31 papers, 753 citations indexed

About

G. S. Falchook is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G. S. Falchook has authored 31 papers receiving a total of 753 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 13 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. S. Falchook's work include PI3K/AKT/mTOR signaling in cancer (13 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). G. S. Falchook is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (13 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). G. S. Falchook collaborates with scholars based in United States and United Kingdom. G. S. Falchook's co-authors include Razelle Kurzrock, Richard Kefford, Georgina V. Long, Peter F. Lebowitz, J. R. Infante, M.J. Millward, Michael P. Brown, Hendrik‐Tobias Arkenau, David S. Hong and Apostolia M. Tsimberidou and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

G. S. Falchook

30 papers receiving 739 citations

Peers

Countries citing papers authored by G. S. Falchook

Since Specialization

Citations

This map shows the geographic impact of G. S. Falchook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. S. Falchook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. S. Falchook more than expected).

Fields of papers citing papers by G. S. Falchook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. S. Falchook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. S. Falchook. The network helps show where G. S. Falchook may publish in the future.

Co-authorship network of co-authors of G. S. Falchook

This figure shows the co-authorship network connecting the top 25 collaborators of G. S. Falchook. A scholar is included among the top collaborators of G. S. Falchook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. S. Falchook. G. S. Falchook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors 2014 ·Investigational New Drugs ·David S. Hong, Haby Henary, G. S. Falchook, Aung Naing, Siqing Fu, Stacey Moulder, Jennifer J. Wheler, Apostolia M. Tsimberidou, Jean‐Bernard Durand, Rabia Khan, Pei Yang, Mary Johansen, Robert A. Newman, Razelle Kurzrock	58
2	Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes 2013 ·Annals of Oncology ·Haby Henary, David S. Hong, G. S. Falchook, Apostolia M. Tsimberidou, Goldy C. George, Sijin Wen, Jennifer J. Wheler, Siqing Fu, (unknown), Sarina A. Piha‐Paul, (unknown), (unknown), Wuh‐Liang Hwu, Razelle Kurzrock	14
3	Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience 2012 ·Annals of Oncology ·Jennifer J. Wheler, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, G. S. Falchook, Siqing Fu, Stacy Moulder, Bettzy Stephen, Sijin Wen, Razelle Kurzrock	14
4	18 Pursuing Molecular Stratification in Phase I Trials 2012 ·European Journal of Cancer ·Razelle Kurzrock, Apostolia M. Tsimberidou, David S. Hong, (unknown), G. S. Falchook, (unknown), (unknown), (unknown), Shilei Wen, Don Berry	1
5	Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy 2012 ·Annals of Oncology ·Jennifer J. Wheler, G. S. Falchook, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Sarina A. Piha‐Paul, (unknown), Siqing Fu, Bettzy Stephen, Jansina Y. Fok, Filip Jankú, Razelle Kurzrock	21
6	Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). 2011 ·Journal of Clinical Oncology ·Razelle Kurzrock, Akash Patnaik, (unknown), Sidney W. Fu, Kyriakos P. Papadopoulos, Deborah A. Smith, G. S. Falchook, (unknown), Jennifer Gauvin, Aung Naing, Lon Smith, Teresita Pérez González, Apostolia M. Tsimberidou, Theresa A. Mays, Donna S. Cox, David S. Hong, Douglas J. DeMarini, (unknown), Shannon R. Morris, A. W. Tolcher	26
7	Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. 2011 ·Journal of Clinical Oncology ·Filip Jankú, Ignacio Garrido‐Laguna, Jennifer J. Wheler, David S. Hong, Aung Naing, G. S. Falchook, Siqing Fu, Stacy Moulder, Rajyalakshmi Luthra, J. Jack Lee, Apostolia M. Tsimberidou, Razelle Kurzrock	4
8	Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). 2011 ·Journal of Clinical Oncology ·J. R. Infante, G. S. Falchook, Donald P. Lawrence, (unknown), Richard Kefford, Johanna C. Bendell, Razelle Kurzrock, Geoffrey I. Shapiro, Ragini R. Kudchadkar, Georgina V. Long, Howard A. Burris, (unknown), Arthur Clements, Shuying Peng, (unknown), Alicia J. Allred, Danièle Ouellet, (unknown), Peter F. Lebowitz, Keith T. Flaherty	101
9	Survival of 1,181 patients in a phase I clinic: The University of Texas M. D. Anderson Cancer Center experience. 2011 ·Journal of Clinical Oncology ·(unknown), (unknown), Apostolia M. Tsimberidou, Shuxin Wen, Aung Naing, David S. Hong, G. S. Falchook, Sarina A. Piha‐Paul, Siqing Fu, Filip Jankú, Stacy L. Moulder, Razelle Kurzrock	1
10	Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients. 2011 ·Journal of Clinical Oncology ·Haby Henary, Razelle Kurzrock, G. S. Falchook, Aung Naing, Stacy L. Moulder, Jennifer J. Wheler, Apostolia M. Tsimberidou, Jean‐Bernard Durand, (unknown), Mary Johansen, Robert H. Newman, Rabia Khan, Urvi Patel, David S. Hong	11
11	Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies. 2011 ·Journal of Clinical Oncology ·Santosh Kumar Sharma, Razelle Kurzrock, Launce Gouw, David S. Hong, (unknown), Xiaofei Zhou, Huidong Shi, Howard Fingert, G. S. Falchook	7
12	An umbrella protocol for histology-independent, phase I modular study based on EGFR mutation status: Using erlotinib alone or in combination with cetuximab, bortezomib, or dasatinib to overcome resistance. 2011 ·Journal of Clinical Oncology ·Jansina Y. Fok, Razelle Kurzrock, Apostolia M. Tsimberidou, (unknown), (unknown), David S. Hong, Filip Jankú, G. S. Falchook, Sarina A. Piha‐Paul, Richard J. Katz, Siqing Fu, Stacy Moulder, Jennifer J. Wheler	2
13	Phosphatase and tensin homologue (PTEN) loss and response to phase I trials targeting PI3K/AKT/mTOR pathway in patients with advanced cancer. 2010 ·Journal of Clinical Oncology ·Ignacio Garrido‐Laguna, Filip Jankú, Apostolia M. Tsimberidou, (unknown), G. S. Falchook, Siqing Fu, (unknown), Aung Naing, Sarina A. Piha‐Paul, Razelle Kurzrock	5
14	Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center experience. 2010 ·Journal of Clinical Oncology ·(unknown), Apostolia M. Tsimberidou, Shilei Wen, Aung Naing, David S. Hong, G. S. Falchook, Sarina A. Piha‐Paul, Siqing Fu, Stacy Moulder, Razelle Kurzrock, (unknown)	1
15	Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies. 2010 ·Journal of Clinical Oncology ·(unknown), G. S. Falchook, Siqing Fu, Aung Naing, David S. Hong, Weiheng Hu, Stacy Moulder, (unknown), Anjla Sood, Razelle Kurzrock	2
16	Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. 2010 ·Journal of Clinical Oncology ·Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown, M.J. Millward, J. R. Infante, Georgina V. Long, (unknown), (unknown), Peter F. Lebowitz, G. S. Falchook	219
17	373 The oral MEK1/MEK2 inhibitor, GSK1120212, effectively inhibits the MAPK pathway: pharmacokinetic, pharmacodynamic, and clinical response relationship 2010 ·European Journal of Cancer Supplements ·M.S. Gordon, J. R. Infante, W. Messersmith, Leslie A. Fecher, N. Vogelzang, Donna S. Cox, Douglas J. DeMarini, Ying Xu, Vijay Peddareddigari, G. S. Falchook	1
18	Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment 2009 ·Annals of Oncology ·G. S. Falchook, Francisco Vega, Nam H. Dang, Felipe Samaniego, Maria Alma Rodriguez, Richard E. Champlin, Chitra Hosing, Srđan Verstovšek, Barbara Pro	105
19	Hypoxia-inducible factor-1α (HIF-1α) modulation in combination with anti-angiogenic therapy 2009 ·Journal of Clinical Oncology ·G. S. Falchook, Jennifer J. Wheler, Nizar M. Tannir, Aung Naing, Edward F. Jackson, David S. Hong, Kristie Lawhorn, (unknown), Hesham M. Amin, Razelle Kurzrock	1
20	A first-in-human phase I trial of PBI-05204 (oleandrin), an inhibitor of Akt, FGF-2, NF-Kb, and p70S6K in advanced solid tumor patients 2009 ·Journal of Clinical Oncology ·(unknown), Razelle Kurzrock, G. S. Falchook, Aung Naing, Jennifer J. Wheler, Jean‐Bernard Durand, Peiying Yang, Mary Johansen, Robert A. Newman, Rabia Khan, David S. Hong	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact